198 related articles for article (PubMed ID: 33076776)
1. Preablation Diagnostic Whole-Body Scan vs Empiric Radioactive Iodine Ablation in Differentiated Thyroid Cancer: Cost-effectiveness Analysis.
Arjani S; Quinn PL; Chokshi RJ
Otolaryngol Head Neck Surg; 2021 Jun; 164(6):1172-1178. PubMed ID: 33076776
[TBL] [Abstract][Full Text] [Related]
2. To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States.
Wang TS; Cheung K; Mehta P; Roman SA; Walker HD; Sosa JA
J Clin Endocrinol Metab; 2010 Apr; 95(4):1672-80. PubMed ID: 20139234
[TBL] [Abstract][Full Text] [Related]
3. Differentiated thyroid carcinoma: Incremental diagnostic value of
Zilioli V; Peli A; Panarotto MB; Magri G; Alkraisheh A; Wiefels C; Rodella C; Giubbini R
Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475
[TBL] [Abstract][Full Text] [Related]
4. Total thyroidectomy is more cost-effective than radioactive iodine as an alternative to antithyroid medication for Graves' disease.
Ma EZ; Kuo JH; Malek R; Turner DJ; Olson JA; Slejko JF; Mullins CD; Hu Y
Surgery; 2023 Jan; 173(1):193-200. PubMed ID: 36208983
[TBL] [Abstract][Full Text] [Related]
5. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.
Fleeman N; Houten R; Bagust A; Richardson M; Beale S; Boland A; Dundar Y; Greenhalgh J; Hounsome J; Duarte R; Shenoy A
Health Technol Assess; 2020 Jan; 24(2):1-180. PubMed ID: 31931920
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of 18F-FDG PET/CT in detecting suspected recurrence or metastasis in well-differentiated thyroid carcinoma patients with negative diagnostic total body scan in Thailand: a decision analysis.
Khiewvan B; Nopmaneejumruslers C; Pusuwan P; Tuchinda P; Tojinda N; Ubolnuch K
J Med Assoc Thai; 2013 Oct; 96(10):1350-64. PubMed ID: 24350419
[TBL] [Abstract][Full Text] [Related]
7. Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer.
Iwano S; Ito S; Kamiya S; Ito R; Kato K; Naganawa S
Nagoya J Med Sci; 2020 May; 82(2):205-215. PubMed ID: 32581401
[TBL] [Abstract][Full Text] [Related]
8. Timing of post 131I ablation diagnostic whole body scan in differentiated thyroid cancer patients. Less than four months post ablation may be too early.
Winter M; Winter J; Heinzel A; Behrendt FF; Krohn T; Mottaghy FM; Verburg FA
Nuklearmedizin; 2015; 54(4):151-7. PubMed ID: 26028188
[TBL] [Abstract][Full Text] [Related]
9. High thyroglobulin and negative whole-body scan: no long-term benefit of empiric radioiodine therapy.
Tramontin MY; Nobre GM; Lopes M; Carneiro MP; Alves PAG; de Andrade FA; Vaisman F; Corbo R; Bulzico D
Endocrine; 2021 Aug; 73(2):398-406. PubMed ID: 33570724
[TBL] [Abstract][Full Text] [Related]
10. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
[TBL] [Abstract][Full Text] [Related]
11. No adverse affect in clinical outcome using low preablation diagnostic (131)i activity in differentiated thyroid cancer: refuting thyroid-stunning effect.
Yap BK; Murby B
J Clin Endocrinol Metab; 2014 Jul; 99(7):2433-40. PubMed ID: 24762114
[TBL] [Abstract][Full Text] [Related]
12. Routine prophylactic central neck dissection for low-risk papillary thyroid cancer is not cost-effective.
Garcia A; Palmer BJ; Parks NA; Liu TH
Clin Endocrinol (Oxf); 2014 Nov; 81(5):754-61. PubMed ID: 24862564
[TBL] [Abstract][Full Text] [Related]
13. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
[TBL] [Abstract][Full Text] [Related]
14. Differentiated thyroid cancer: lobectomy and radioiodine, a treatment suitable for all cases?
Allan E; Owens SE; Waller ML
Nucl Med Commun; 1999 Nov; 20(11):983-9. PubMed ID: 10572907
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing radioiodine uptake after thyroid cancer surgery.
Bai JB; Shakerian R; Westcott JD; Lichtenstein M; Miller JA
ANZ J Surg; 2015; 85(7-8):572-7. PubMed ID: 23964714
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: the Canadian perspective.
Mernagh P; Suebwongpat A; Silverberg J; Weston A
Value Health; 2010; 13(2):180-7. PubMed ID: 19818064
[TBL] [Abstract][Full Text] [Related]
17. Radioiodine or surgery for toxic thyroid adenoma: dissecting an important decision. A cost-effectiveness analysis.
Vidal-Trecan GM; Stahl JE; Eckman MH
Thyroid; 2004 Nov; 14(11):933-45. PubMed ID: 15671772
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer treatment in Spanish hospitals.
Vallejo JA; Muros MA
Rev Esp Med Nucl Imagen Mol; 2017; 36(6):362-370. PubMed ID: 28539216
[TBL] [Abstract][Full Text] [Related]
19. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer.
Mandel SJ; Shankar LK; Benard F; Yamamoto A; Alavi A
Clin Nucl Med; 2001 Jan; 26(1):6-9. PubMed ID: 11139058
[TBL] [Abstract][Full Text] [Related]
20. Higher preablative serum thyroid-stimulating hormone level predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.
Lawal IO; Nyakale NE; Harry LM; Lengana T; Mokgoro NP; Vorster M; Sathekge MM
Nucl Med Commun; 2017 Mar; 38(3):222-227. PubMed ID: 28002173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
